Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (11) , 2220-2229
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 29 references indexed in Scilit:
- ACE Inhibitor and Angiotensin Receptor-II Antagonist Prescribing and Hospital Admissions with Acute Kidney Injury: A Longitudinal Ecological StudyPLOS ONE, 2013
- Effects of zofenopril on myocardial ischemia in post–myocardial infarction patients with preserved left ventricular function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)–ISCHEMIA studyAmerican Heart Journal, 2007
- “Renalism”Journal of the American Society of Nephrology, 2004
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothNew England Journal of Medicine, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- Predictors of the Development of Hyperkalemia in Patients Using Angiotensin-Converting Enzyme InhibitorsAmerican Journal of Nephrology, 2000
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarctionJACC, 1999
- Diuretic-induced hypokalemiaKidney International, 1985